Skip to content
value.today

MyoKardia Inc

Total raised
$60 M
3 rounds on record
Latest round
$46 M
Apr 2015
First round on record
Sep 2012
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of MyoKardia Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2015$46 MNo. 3$10 to $50 million

MyoKardia Inc: Raise no. 3, Apr 2015

Investors in this round

9 investors had bought by the notice of Apr 30, 2015: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for MyoKardia Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$46 M of $46 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Tassos Anastasios Gianakakos · Executive Officer, Director
  • Charles Homcy · Director
  • Katherine Bowdish · Director
  • Kevin Starr · Director
  • Mark Perry · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “The Issuer will use proceeds for general working capital purposes which includes payments to its executive officers and other employees in the ordinary course of business.”

Signed by T. Anastasios Gianakakos, CEO and President. Source: SEC Form D, newest notice filed Apr 30, 2015. Read the notice at the SEC.

equitySEC
Aug 2014$10 MNo. 2$10 to $50 million

MyoKardia Inc: Raise no. 2, Aug 2014

Investors in this round

1 investor had bought by the notice of Aug 22, 2014: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for MyoKardia Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Tassos Anastasios Gianakakos · Executive Officer, Director
  • Charles Homcy · Director
  • Katherine Bowdish · Director
  • Kevin Starr · Director
  • Mark Perry · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by T. Anastasios Gianakakos, CEO and President. Source: SEC Form D, newest notice filed Aug 22, 2014. Read the notice at the SEC.

equitySEC
Sep 2012$4 MNo. 1$2 to $10 million

MyoKardia Inc: Raise no. 1, Sep 2012

Investors in this round

1 investor had bought by the notice of Oct 3, 2012: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for MyoKardia Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $38 M offered; $34 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles Homcy · Executive Officer, Director
  • Kevin Starr · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Charles Homcy, CEO and President. Source: SEC Form D, newest notice filed Oct 3, 2012. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • MyoKardia Inc chose not to state its revenue in its newest notice of a funding round (Apr 2015).

    SEC Form D · Apr 2015

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Apr 2015

That is all the official record says: MyoKardia Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in MyoKardia Inc
InvestorKindAmountRoundRoleSource
Third Rock Ventures GP III, L.P.Venture capitalnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Third Rock Ventures GP II, L.P.Venture capitalnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Third Rock Ventures III, L.P.Venture capitalnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Third Rock Ventures II, L.P.Venture capitalnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2015)SEC Form 3
TRV GP III, LLCOthernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2015)SEC Form 3
TRV GP II, LLCOthernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2015)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 9 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by MyoKardia Inc
NameRoleNamed in
Tassos Anastasios GianakakosExecutive officerApr 2015
Charles HomcyExecutive officerOct 2012
Charles HomcyDirectorApr 2015
Katherine BowdishDirectorApr 2015
Kevin StarrDirectorApr 2015
Mark PerryDirectorApr 2015
Tassos Anastasios GianakakosDirectorApr 2015